WordNet

used to express refusal or denial or disagreement etc or especially to emphasize a negative statement; "no, you are wrong"
a negative; "his no was loud and clear"
referring to the degree to which a certain quality is present; "he was no heavier than a child" (同)no more
not in any degree or manner; not at all; "he is no better today"
quantifier; used with either mass nouns or plural count nouns for indicating a complete or almost complete lack or zero quantity of; "we have no bananas"; "no eggs left and no money to buy any"; "have you no decency?"; "did it with no help"; "Ill get you there in no time"
make ones way by force; "He muscled his way into the office"
animal tissue consisting predominantly of contractile cells (同)muscular_tissue
one of the contractile organs of the body (同)musculus
authority or power or force (especially when used in a coercive way); "the senators used their muscle to get the party leader to resign"
relating to a technique in which the body is entered by puncture or incision
marked by a tendency to spread especially into healthy tissue; "invasive cancer cells"
type genus of the family Cancridae (同)genus Cancer
the fourth sign of the zodiac; the sun is in this sign from about June 21 to July 22 (同)Cancer the Crab, Crab
(astrology) a person who is born while the sun is in Cancer (同)Crab
a small zodiacal constellation in the northern hemisphere; between Leo and Gemini
any malignant growth or tumor caused by abnormal and uncontrolled cell division; it may spread to other parts of the body through the lymphatic system or the blood stream (同)malignant neoplastic disease

PrepTutorEJDIC

《名詞の前に置いて》『一つも』(『一人も,少しも』)・・・『ない』 / 《補語につけて》『決して・・・でない』 / 《省略文で》・・・なし;・・・お断り / 《話》少ししか(あまり)・・・ない / (肯定の問いに対して)『いいえ』;(否定の問いに対して)はい,ええ / 《not, norの前に挿入して》『いや』,否 / 《形容詞の前に置その形容詞を否定して》…どころではない / 《比較級の前に置いて》ちっとも…でない,…と全く同じ / 《… or no の形で》…であってもなくても / 《驚き・困惑・不信などを表して》とんでもない / 《単数形で》『拒否』,「『いいえ』」という返事 / 《複数形で》反対[投]票
〈U〉(動物体の組織としての)『筋肉』,筋(きん);〈C〉(体の各部を動かす)筋肉 / 〈U〉力,(特に)筋力,腕力 / 《俗に》(…に)強引に割り込む《+『in on』(『into, through』)+『名』》
(戦争などが)侵略的な / (言葉などが)立ち入った,出過ぎた
〈U〉〈C〉『がん』 / 〈U〉〈C〉害悪 / 《Cancer》(星座の)カニ座

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 筋層非浸潤性膀胱癌の治療 treatment of non muscle invasive bladder cancer
2. 尿路上皮膀胱癌の初期アプローチおよびマネージメントの概要 overview of the initial approach and management of urothelial bladder cancer
3. 膀胱癌の臨床症状、診断、および病期分類 clinical presentation diagnosis and staging of bladder cancer
4. 尿路上皮膀胱癌に対する根治的膀胱全摘除術および膀胱温存治療 radical cystectomy and bladder sparing treatments for urothelial bladder cancer
5. Bladder preservation treatment options for muscle-invasive urothelial bladder cancer

English Journal

Circulating tumor cells in early bladder cancer: insight into micrometastatic disease.

Raimondi C1, Gradilone A, Gazzaniga P.Author information 1Dipartimento Medicina Molecolare, Sapienza Università di Roma, Viale Regina Elena 324, 00161 Roma, Italy.AbstractAlthough several studies have demonstrated the prognostic and predictive potential of circulating tumor cells (CTCs), to date their evaluation still has not impacted the treatment strategy. There is wide consensus that CTC assessment would be more beneficial in early stage cancer, especially in those tumor types characterized by early progression and a lack of prognostic markers. Non-muscle-invasive bladder cancer represents an optimal model to this purpose. In fact, the rate of metastatic spread ranges between 20 and 40%, which is unacceptable for a 'superficial' tumor and unexpected in an early stage cancer. This may be due to the presence of non-clinically detectable micrometastases. CTCs may be used as a noninvasive, real-time tool for the stratification of early stage bladder cancer patients according to individual risk of progression.
Expert review of molecular diagnostics.Expert Rev Mol Diagn.2014 May;14(4):407-9. doi: 10.1586/14737159.2014.908119. Epub 2014 Apr 10.
Although several studies have demonstrated the prognostic and predictive potential of circulating tumor cells (CTCs), to date their evaluation still has not impacted the treatment strategy. There is wide consensus that CTC assessment would be more beneficial in early stage cancer, especially in thos
PMID 24717055

Significance of uroplakin III expression in recurrence of solitary muscle non-invasive bladder cancer.

Tadin T1, Krpina K2, Stifter S3, Babarović E4, Jonjić N3.Author information 1Ultrasound Diagnostic Service, Health Centre Rijeka, Martina Kontuša 18, 51000 Rijeka, Croatia.2Department of Urology, Rijeka University Hospital Center, T. Stržića 3, Rijeka, Croatia.3Department of Pathology, School of Medicine, University of Rijeka, Braće Branchetta 20, Rijeka, Croatia.4Department of Pathology, School of Medicine, University of Rijeka, Braće Branchetta 20, Rijeka, Croatia. Electronic address: esinozic@gmail.com.AbstractNumerous immunohistochemical biomarkers for patients with urothelial bladder cancer have been identified in order to predict their biological behavior. The aim of this present study was to examine the uroplakin III (UPIII) expression in homogenous group of non-muscle invasive bladder cancer and to correlate its value with clinico-pathological characteristics of patients and moreover with COX-2 expression and tumor infiltrating lymphocytes (TILs). Tumor specimens from 127 patients with non-muscle invasive bladder cancer, divided into two groups: patients who developed recurrent disease during the first five post-operative years (N=78) and patients without recurrent disease during a follow-up of minimum 5 years (N=49), were retrieved for tissue microarrays construction. On paraffin sections, the immunohistochemical analysis of UPIII expression was performed and staining was semiquantitatively evaluated. Expression of UPIII, including luminal, membranous and cytoplasmic one, was found in more than half of the tumors (57%). Specific staining pattern for UPIII was not associated with age and gender of patients, pathological grade, tumor size, disease stage or recurrence of disease. There was no association between UPIII, COX-2 and TILs, except for a negative moderate association between UP and COX-2 in the group of patients without recurrent tumor, and a strong association between UPIII and in the group with tumor recurrence. The present work gives an insight into the very complex mechanisms involved in tumor biology and progression. Moreover, it highlights the importance of further studies that should include multiple molecular markers in models designed to predict the outcome of non-muscle invasive bladder cancer.
Pathology, research and practice.Pathol Res Pract.2014 May;210(5):279-84. doi: 10.1016/j.prp.2014.01.003. Epub 2014 Jan 31.
Numerous immunohistochemical biomarkers for patients with urothelial bladder cancer have been identified in order to predict their biological behavior. The aim of this present study was to examine the uroplakin III (UPIII) expression in homogenous group of non-muscle invasive bladder cancer and to c
PMID 24553301

Novel Green-light KTP Laser en bloc Enucleation for Non-Muscle-Invasive Bladder Cancer: Technique and Initial Clinical Experience.

He D1, Fan J, Wu K, Wang X, Wu D, Li L, Li X, Liu L, Cao P, Cao J, Chang LS.Author information 1First Affiliated Hospital of Medical School, Xi'an Jiaotong University, Department of Urology, #277, Yanta West Rd., Xi'an, China, 710061 ; dalinhe@yahoo.com.AbstractBackground and Purpose: The standard procedure for staging and treating non-muscle-invasive bladder cancer (NMIBC) is still transurethral resection of the bladder tumor (TURBT) via a wire loop. However, TURBT is associated with serious disadvantages that facilitate tumor recurrence. Recently, lasers have been explored as treatment tools for bladder tumors. Here, we report a novel tumor en bloc enucleation using a front-firing green-light potassium-titanyl-phosphate laser and its initial clinical application. Patients and Methods: From March through June 2013, 45 patients with NMIBC received modified transurethral resection using a front-firing green-light laser. En bloc enucleation was performed on all tumors. Preoperative and intraoperative data were retrospectively collected. Results: All patients successfully went through a session of treatment with front-firing green-light laser enucleation of the bladder tumor. Complications such as bladder hemorrhage, vesicle perforation and obturator nerve reflex were not encountered during the treatment. The tumor diameter ranges from 0.3 to 3.0 cm with a mean value of 1.8 cm. Mean operative time and enucleation time were 21 (12-38) and 12 (4-23) minutes, respectively. Serum hemoglobin decreased 1.1 (0.1-2.4) mg/dl averagely. Mean catheter time was 2.0 (1.0-3.0) days, and mean postoperative hospital stay was 2.5 (1.5-4.0) days. The stages of bladder cancer included 27 Ta, 15 T1, and 3 T2a. No tumor recurrence was observed at the initial 6-month follow-up. Conclusions: The modified technique using a front-firing green-light laser to en bloc enucleate bladder tumors is effective and safe for treatment of NMIBC. Moreover, it may improve the accurate valuation of tumor stage and prediction of postoperative prognosis, although long-term outcomes and prospective clinical trials are needed.
Journal of endourology / Endourological Society.J Endourol.2014 Apr 16. [Epub ahead of print]
Background and Purpose: The standard procedure for staging and treating non-muscle-invasive bladder cancer (NMIBC) is still transurethral resection of the bladder tumor (TURBT) via a wire loop. However, TURBT is associated with serious disadvantages that facilitate tumor recurrence. Recently, lasers
PMID 24735433

Japanese Journal

Lung metastasis of ta bladder cancer: a case report and literature review.

Sano Takeshi,Hamada Shinshichi,Haitani Takao,Nakashima Masakazu,Kajita Yoichiro,Shichiri Yasumasa
Korean journal of urology 54(4), 271-273, 2013-04-00
… A 66-year-old man with a history of multiple transurethral resections for recurrent bladder tumors, staged as Ta according to the International Union Against Cancer staging guidelines, presented with a complaint of dry cough. … Pulmonary metastasis of recurrent bladder cancer was diagnosed by immunohistochemistry staining for the urothelium-specific protein uroplakin Ia. …
NAID 120005244660

筋層非浸潤性膀胱癌に対するBCG/epirubicin交替膀胱内注入維持療法の有効性と安全性

池田勝臣,元島崇信,黒澤和宏,藤井陽一,宮川仁平,上垣内崇行,細田千尋,小松秀樹,岡根谷利一
泌尿器科紀要 59(3), 153-157, 2013-03-00
… The objectives of this study were to evaluate the efficacy and toxicity of maintenance intravesical instillation therapy with bacillus Calmette-Guerin (BCG) and epirubicin for non-muscle invasive bladder cancer. …
NAID 120005244609

Related Pictures

Highlighting Clinical Trials: Non-Muscle Invasive Bladder Cancer (Part I) - YouTube Staging and grading of bladder cancer - Macmillan Cancer Support Non-Muscle-Invasive Bladder Cancer: Review of Diagnosis and Management | HealthPlexus.net What’s new in high-risk non-muscle invasive bladder cancer? – EAUN17 London Intravesical Gene Therapy for Non-Muscle Invasive Bladder Cancer - ACE Oncology Staging and grading non-invasive bladder cancer - Understanding - Macmillan Cancer Support Management of Non-Muscle Invasive Bladder Cancer HLA-E and NKG2A as a novel immune checkpoint axis to improve treatment for non-muscle